ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.159,38
-0,04%
S&P 500
5.185,61
-0,04%
US Dollar vs BRL
5,0973
0,44%
Bitcoin
62.717,48
0,61%
Brent Oil
83,345
0,58%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Pharming Group NV (PHAR)

  7. Pharming Group NV (PHAR) Notícias

PHAR

Pharming Group NV (PHAR)

Pharming Group NV
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PHAR
DataHoraFonteTítuloCódigoCompanhia
08/05/202407:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202303:00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202302:00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202302:00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
03/08/202302:00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202302:00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202303:00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202307:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202302:00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202303:00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
17/05/202312:28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202302:00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202303:00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202303:00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202302:36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202308:11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202302:00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
05/04/202307:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PHARPharming Group NV
05/04/202303:00PR Newswire (US)Pharming Group convenes the Annual General Meeting of Shareholders 2023NASDAQ:PHARPharming Group NV
05/04/202302:00PR Newswire (US)Pharming Group announces the filing of its 2022 Annual Report and Form 20-FNASDAQ:PHARPharming Group NV
30/03/202311:39PR Newswire (US)Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease DaysNASDAQ:PHARPharming Group NV
24/03/202320:22Dow Jones NewsADRs End Mostly Lower, Pharming Group Trades ActivelyNASDAQ:PHARPharming Group NV
24/03/202315:35PR Newswire (US)Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDSNASDAQ:PHARPharming Group NV
13/03/202306:43PR Newswire (US)Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcementNASDAQ:PHARPharming Group NV
13/03/202305:34Dow Jones NewsPharming Expects to Have Access to $26 Million It Has on Deposit at SVB USNASDAQ:PHARPharming Group NV
13/03/202304:15PR Newswire (US)Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcementNASDAQ:PHARPharming Group NV
12/03/202315:30PR Newswire (US)Pharming Group issues statement regarding the events surrounding Silicon Valley BankNASDAQ:PHARPharming Group NV
28/02/202303:00PR Newswire (US)Notice of Full Year 2022 financial resultsNASDAQ:PHARPharming Group NV
21/02/202303:00PR Newswire (US)Pharming announces first patient enrolled in pediatric clinical trial of leniolisibNASDAQ:PHARPharming Group NV
16/02/202303:00PR Newswire (Canada)Pharming provides update on EMA regulatory review of leniolisib for APDS in EuropeNASDAQ:PHARPharming Group NV
 Apresentando as notícias mais relevantes sobre:NASDAQ:PHAR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
ETER3
ETERNIT ON
BOV
COGN3
COGNA ON
BOV
VVEO3
CM Hospitalar ON
BOV
PRIO3
PETRORIO ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
CRFB3
CARREFOUR ON
BOV
SGPS3
SPRINGS ON
BOV
TELB4
TELEBRAS PN
BOV
BRKM5
BRASKEM PNA
BOV
GFSA3
GAFISA ON
BOV
RNEW4
RENOVA PN
BOV
JHSF3
JHSF PART ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados